Chardan Capital Reiterates Buy on Tenaya Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Tenaya Therapeutics (NASDAQ:TNYA) and maintained a $20 price target.

March 21, 2024 | 4:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital maintains a Buy rating and a $20 price target on Tenaya Therapeutics.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst like Geulah Livshits from Chardan Capital is likely to instill confidence among investors and could positively influence Tenaya Therapeutics' stock price in the short term. Analyst ratings, especially those that are positive, often lead to increased investor interest and can drive up the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100